In brief

BlauBlau FarmacêuticaOrganizationHospital and biologic drugmaker, listed on B3 as BLAU3.Open in the Market Map ↗ posted recurring profit of R$ 69 million in 3Q26.

Revenue rose 7%.

What we know

04

  1. Verified fact · material

    BlauBlau FarmacêuticaOrganizationHospital and biologic drugmaker, listed on B3 as BLAU3.Open in the Market Map ↗ Farmacêutica posted recurring net income of R$ 69 million in 3Q26, down 5% from 3Q25.

    Profit.

    Sources[01][02]

  2. Verified fact · material

    Net revenue was R$ 506 million, up 7%, and recurring Ebitda rose 12%.

    Revenue.

    Sources[01][02]

  3. Verified fact

    Excluding currency effects, recurring profit would be R$ 79 million, up 7%.

    Currency.

    Sources[01][02]

  4. Verified fact

    According to CNN Brasil, recurring Ebitda was R$ 128 million.

    Ebitda.

    Sources[01]

Transmission to assets

Market read-through

Operations grow, but currency trims profit.

Portfolio impact

01
BLAU3uncertain

Lower profit.

Weak real.

What would change the view: Stable currency.

direct5% confidence

Direction is an explanatory hypothesis, not a forecast or recommendation.

Next signals

What to watch

  • New lines
  • Currency

Limits of the reporting

What remains uncertain

  • Sources differ on the explanation of the decline.

Full sources

02
01
CNN Brasil MoneyBlau Farmacêutica tem lucro de R$ 69 milhões no 3º tri, recuo de 5%independent newsroom
02
Money TimesBlau Farmacêutica (BLAU3) tem lucro recorrente de R$ 69 mi no 3º trimestreindependent newsroom